<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01303939</url>
  </required_header>
  <id_info>
    <org_study_id>10-009</org_study_id>
    <nct_id>NCT01303939</nct_id>
  </id_info>
  <brief_title>Does Glaucoma Cause Loss of Brain Function?</brief_title>
  <official_title>Neuroimaging Brain Changes in Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wills Eye</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wills Eye</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if glaucoma is associated with neurodegenerative
      changes in areas of the brain other than the occipital lobe. This will help guide the
      direction of further research in the use of neuroprotective agents in preventing or
      controlling such changes. The final goal is to improve the quality of life for patients with
      glaucoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Death of retinal ganglion cells causes loss of neurons in areas other than just the visual
      cortex. These neurodegenerative changes decrease the patient's ability to perform the
      activities of daily living. Tensor-based morphometry analysis of magnetic resonance imaging
      (MRI) brain scans will reveal areas of cortical degeneration in glaucoma patients, and the
      extent of damage in these areas should correlate with patients ability to perform
      vision-dependent tasks, as measured by the Assessment of Ability Related to Vision (AARV).

      Patients with glaucoma who were outliers in two previous studies, Assessment of Ability
      Related to Vision (AARV) or Assessment of Disability related to vision (ADREV), in that they
      had poor performance-based measure scores despite having midrange visual field scores.

      Mini-Mental State Exam and T-1 weighted MRI brain scan and will be performed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2010</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Magnetic resonance images (MRI) of the brain were obtained from glaucoma patients to look at structures and volume. Age, gender, ethnic healthy matches for each glaucoma patient received MRIs of the brain for comparison.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute Brain Volume (Size)</measure>
    <time_frame>2 hours</time_frame>
    <description>Absolute volume (size) of inferior occipital gyrus L (a location in the brain structure) is measured in cubic millimeters (mm3).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative Volumes</measure>
    <time_frame>2 hours</time_frame>
    <description>Relative volume is calculated by dividing the absolute volume of inferior occipital gyrus L (a location in the brain structure) by that individual's total brain volume.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Glaucoma Patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients who were outliers from two previous studies: Assessment of Ability Related to Vision (AARV) or Assessment of Disability Related to Vision (ADREV) with mini mental status exam score of 25 or higher underwent magnetic resonance imaging (MRI) of the brain to look at structures and volume.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Age, gender and race matched (to each glaucoma patient) group of healthy individuals with no ocular diseases with mini mental status exam score of 25 or higher underwent magnetic resonance imaging (MRI) of the brain to look at structures and volume.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>magnetic resonance imaging (MRI) of the brain</intervention_name>
    <description>High resolution three-dimensional T1-weighted magnetic resonance imaging (MRI) was obtained from each participant at one visit.</description>
    <arm_group_label>Control Patients</arm_group_label>
    <arm_group_label>Glaucoma Patients</arm_group_label>
    <other_name>Brain MRI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with glaucoma who were participated in other studies Assessment of Ability
             Related to Vision (AARV) or Assessment of Disability Related to Vision (ADREV) and
             were found to be outliers in that they have poor performance-based measure scores (â‰¤
             40) despite having midrange visual field scores (mean deviation of -6 to -20).

          -  Age-, gender- and race-matched controls who do not have glaucoma, and who do not have
             loss of vision for any reason other than cataract or refractive error.

        Exclusion Criteria:

          1. Patients with any type of neurological disease.

          2. Patients with a cognitive deficit which would affect visual functioning, as revealed
             by score of less than 25 in the mini mental status examination.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George L Spaeth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Glaucoma Service, Wills Eye Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wills Eye Institute, Glaucoma Service</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lackey J, Williams AL, Gatla S, Wizov SS, Chia T, Spaeth G, Lai S. Structural changes in glaucoma: A volumetric MRI study. Association for Research in Vision and Ophthalmology, 730/A396May 2012.</citation>
  </results_reference>
  <results_reference>
    <citation>Williams AL, Lackey J, Gatla S, Wizov SS, Sergott R, Chia T, Lai S, Spaeth GL. Correlation of brain volumes and function deficits in glaucoma. 148th Annual AOS Meeting, Charleston, SC 2012.</citation>
  </results_reference>
  <results_reference>
    <citation>Williams AL. Correlation of brain volumes and patient-reported visual disability in glaucoma. AGS Annual Meeting, San Francisco, March 1, 2012</citation>
  </results_reference>
  <results_reference>
    <citation>Williams AL, Lackey J, Wizov S, Gatla S, Sergott R, Chia T, Lai S, Spaeth GL. Correlation of brain volumes and functional deficits in glaucoma. Association of Research in Vision and Ophthalmology, 5624 May 10, 2012.</citation>
  </results_reference>
  <results_reference>
    <citation>Spaeth Gl, Williams AL, Lackey J, Gatla S, Wizov SS, Sergot R, Chia T, Lai S. Glaucoma and the whole patient. AAO 2012 Joint Meeting, Chicago Nov 12, 2012.</citation>
  </results_reference>
  <results_reference>
    <citation>Williams AL, Lackey J, Wizov SS, Chia TM, Gatla S, Moster ML, Sergott R, Spaeth GL, Lai S. Evidence for widespread structural brain changes in glaucoma: a preliminary voxel-based MRI study. Invest Ophthalmol Vis Sci. 2013 Aug 28;54(8):5880-7. doi: 10.1167/iovs.13-11776.</citation>
    <PMID>23838767</PMID>
  </results_reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>February 24, 2011</study_first_submitted>
  <study_first_submitted_qc>February 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2011</study_first_posted>
  <results_first_submitted>May 15, 2017</results_first_submitted>
  <results_first_submitted_qc>November 16, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 20, 2018</results_first_posted>
  <last_update_submitted>November 16, 2018</last_update_submitted>
  <last_update_submitted_qc>November 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wills Eye</investigator_affiliation>
    <investigator_full_name>George L. Spaeth MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Glaucoma</keyword>
  <keyword>MRI Brain Scan</keyword>
  <keyword>Voxel-Based Morphometry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>22 glaucoma patients were enrolled in this study. However, 7 age, gender and ethnic matched controls were not found for study comparisons. Therefore, only the 15 glaucoma patients who best matched the controls were included in the published analysis.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Glaucoma Patients</title>
          <description>Patients were outliers from two previous studies: Assessment of Ability Related to Vision (AARV) or Assessment of Disability Related to Vision (ADREV).</description>
        </group>
        <group group_id="P2">
          <title>Control Patients</title>
          <description>Age, gender and race matched (to the glaucoma patients) group of healthy individuals with no ocular diseases.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15">Matched controls not found for comparisons. Only best matched glaucoma patients were included.</participants>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants completed mini mental status examination with score of 25 or greater then received high resolution 3D T1 weighted magnetic resonance imaging. Seven of the glaucoma patients did not have a control for comparison.</population>
      <group_list>
        <group group_id="B1">
          <title>Glaucoma Patients</title>
          <description>Patients who were outliers from the AARV or ADREV Studies.</description>
        </group>
        <group group_id="B2">
          <title>Control Patients</title>
          <description>Age, gender and race matched group of healthy individuals with no ocular diseases.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.1" spread="11.2"/>
                    <measurement group_id="B2" value="65.6" spread="11.3"/>
                    <measurement group_id="B3" value="65.85" spread="11.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Absolute Brain Volume (Size)</title>
        <description>Absolute volume (size) of inferior occipital gyrus L (a location in the brain structure) is measured in cubic millimeters (mm3).</description>
        <time_frame>2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Glaucoma Patients</title>
            <description>Patients who were outliers from the AARV or ADREV Studies.</description>
          </group>
          <group group_id="O2">
            <title>Control Patients</title>
            <description>Age, gender and race matched group of healthy individuals with no ocular diseases.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Brain Volume (Size)</title>
          <description>Absolute volume (size) of inferior occipital gyrus L (a location in the brain structure) is measured in cubic millimeters (mm3).</description>
          <units>cubic millimeters (mm3)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3067" spread="903"/>
                    <measurement group_id="O2" value="2302" spread="357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Volumes</title>
        <description>Relative volume is calculated by dividing the absolute volume of inferior occipital gyrus L (a location in the brain structure) by that individual's total brain volume.</description>
        <time_frame>2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Glaucoma Patients</title>
            <description>Patients who were outliers from two previous studies: Assessment of Ability Related to Vision (AARV) or Assessment of Disability Related to Vision (ADREV) with mini mental status exam score of 25 or higher underwent magnetic resonance imaging (MRI) of the brain to look at structures and volume.
magnetic resonance imaging (MRI) of the brain: High resolution three-dimensional T1-weighted magnetic resonance imaging (MRI) was obtained from each participant at one visit.</description>
          </group>
          <group group_id="O2">
            <title>Control Patients</title>
            <description>Age, gender and race matched (to each glaucoma patient) group of healthy individuals with no ocular diseases with mini mental status exam score of 25 or higher underwent magnetic resonance imaging (MRI) of the brain to look at structures and volume.
magnetic resonance imaging (MRI) of the brain: High resolution three-dimensional T1-weighted magnetic resonance imaging (MRI) was obtained from each participant at one visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Volumes</title>
          <description>Relative volume is calculated by dividing the absolute volume of inferior occipital gyrus L (a location in the brain structure) by that individual's total brain volume.</description>
          <units>cubic millimeters (mm3)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0037" spread="0.001"/>
                    <measurement group_id="O2" value="0.0029" spread="0.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Glaucoma Patients</title>
          <description>Patients who were outliers from the AARV or ADREV Studies.</description>
        </group>
        <group group_id="E2">
          <title>Control Patients</title>
          <description>Age, gender and race matched group of healthy individuals with no ocular diseases.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>George L. Spaeth, MD</name_or_title>
      <organization>Wills Eye Hospital, Glaucoma Research Center</organization>
      <phone>215-928-3123</phone>
      <email>gspaeth@willseye.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

